Developer of drug delivery platform for cancer therapeutics and clinical trials. The company focuses on improving bioavailability of water-insoluble therapeutics while maintaining safety. Their lead drug candidate combines the delivery platform with fenretinide. The company seeks funding and partnerships to assess safety and efficacy. The company was founded in 2001 and headquartered in United States. It has raised $6M in series b funding, with backing from Pointe Angels, Storm Lake Capital, Harlem River Navy, Nfcr, and others. The company operates in the High Tech - Nanotechnology, Life Sciences - Oncology, Life Sciences - Drug Delivery space. Its offerings span Oncology - Drugs - Diversified and Drug Delivery - Nanoparticle Based.
← All startups
SciTech Development
Series BDeveloper of drug delivery platform for cancer therapeutics and clinical trials. The company focuses on improving bioavailability of water-insoluble therapeutics while maintaining safety. Their lead drug candidate combines the delivery platform with fenretinide. The company seeks funding and partnerships to assess safety and efficacy. The company was founded in 2001 and headquartered in United States. It has raised…
About
Business model
Nanotechnology > Nanoenabled Products > Life Science > Drugs > Cancer,
Oncology > Drugs > Diversified,
Drug Delivery > Nanoparticle Based
Institutional investors
Pointe AngelsStorm Lake CapitalHarlem River NavyNfcrHud ExchangeAIM-HI Accelerator FundCity Side Ventures
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.